Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) EPS (Basic) (2022 - 2025)

BioXcel Therapeutics has reported EPS (Basic) over the past 4 years, most recently at $0.65 for Q4 2025.

  • Quarterly results put EPS (Basic) at $0.65 for Q4 2025, up 122.34% from a year ago — trailing twelve months through Dec 2025 was -$5.48 (up 78.3% YoY), and the annual figure for FY2025 was -$5.73, up 75.63%.
  • EPS (Basic) for Q4 2025 was $0.65 at BioXcel Therapeutics, up from -$2.18 in the prior quarter.
  • Over the last five years, EPS (Basic) for BTAI hit a ceiling of $0.65 in Q4 2025 and a floor of -$92.93 in Q4 2023.
  • Median EPS (Basic) over the past 4 years was -$1.9 (2023), compared with a mean of -$8.44.
  • Biggest five-year swings in EPS (Basic): crashed 4641.33% in 2023 and later skyrocketed 122.34% in 2025.
  • BioXcel Therapeutics' EPS (Basic) stood at -$1.96 in 2022, then crashed by 4641.33% to -$92.93 in 2023, then surged by 96.87% to -$2.91 in 2024, then surged by 122.34% to $0.65 in 2025.
  • The last three reported values for EPS (Basic) were $0.65 (Q4 2025), -$2.18 (Q3 2025), and -$2.45 (Q2 2025) per Business Quant data.